APEIRON Biologics at a glance

  • First Austrian biotech company to develop a cancer immunotherapy product through to market
  • Approval in 2017 for treatment of pediatric neuroblastoma in EU and other countries, US/Japan BLA filing in preparation
  • Respiratory drug candidate APN01 in clinical development
  • Oncology pipeline in clinical stages
  • Focused on novel cancer immunotherapies and respiratory treatments
  • Lead by highly experienced and motivated team with global background


APEIRON Biologics and MaxCyte Enter into Clinical and Commercial Licensing Agreement for APN401
APEIRON to utilize MaxCyte’s ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials. 8 July 2020: Press release (EN) | Presseaussendung (DE)
July 8, 2020
APEIRON Biologics closes oversubscribed financing round of EUR 17.5 million for the development of APN01 against COVID-19. Expansion of the ongoing phase II clinical trial to USA and Russia planned.
APEIRON Biologics AG has successfully completed a financing round totaling EUR 17.5 million, thus securing the further development of its drug candidate APN01 for the treatment of seriously ill COVID-19 patients and the further development of immuno-oncology projects. Expansion of the ongoing phase II clinical trial to USA and Russia planned. 3 June 2020: Press...
June 3, 2020
APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01
Substantial financing measures through capital increase with subscription rights and private placement as well as grants Vienna Insurance Group is secured as lead investor of the financing round and secures the private placement Participation in capital increase by existing shareholders as well as new institutional and private investors confirmed Public grant funding committed Financing secures...
May 18, 2020